NO20070468L - Sammensetninger og fremgangsmater for behandling av dyslipidemi - Google Patents

Sammensetninger og fremgangsmater for behandling av dyslipidemi

Info

Publication number
NO20070468L
NO20070468L NO20070468A NO20070468A NO20070468L NO 20070468 L NO20070468 L NO 20070468L NO 20070468 A NO20070468 A NO 20070468A NO 20070468 A NO20070468 A NO 20070468A NO 20070468 L NO20070468 L NO 20070468L
Authority
NO
Norway
Prior art keywords
methods
compositions
dyslipidemia
treatment
compounds
Prior art date
Application number
NO20070468A
Other languages
English (en)
Norwegian (no)
Inventor
Ana Maria Escribano
Nathan Bryan Mantlo
Xiaodong Wang
Maria-Carmen Fernandez
Eva Maria Martin De La Nava
Ana Isabel Mateo-Herranz
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20070468(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20070468L publication Critical patent/NO20070468L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20070468A 2004-06-24 2007-01-24 Sammensetninger og fremgangsmater for behandling av dyslipidemi NO20070468L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US58270804P 2004-06-24 2004-06-24
US62724104P 2004-11-12 2004-11-12
US66486205P 2005-03-24 2005-03-24
PCT/US2005/021789 WO2006012093A1 (fr) 2004-06-24 2005-06-22 Composés et procédés destinés à traiter la dyslipidémie

Publications (1)

Publication Number Publication Date
NO20070468L true NO20070468L (no) 2007-03-12

Family

ID=35056992

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20070470A NO20070470L (no) 2004-06-24 2007-01-24 Sammensetninger og fremgangsmater for behandling av dyslipidemi
NO20070468A NO20070468L (no) 2004-06-24 2007-01-24 Sammensetninger og fremgangsmater for behandling av dyslipidemi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20070470A NO20070470L (no) 2004-06-24 2007-01-24 Sammensetninger og fremgangsmater for behandling av dyslipidemi

Country Status (27)

Country Link
US (3) US20080269284A1 (fr)
EP (3) EP1761521A1 (fr)
JP (2) JP2008504266A (fr)
KR (1) KR20070041452A (fr)
CN (1) CN1972932B (fr)
AT (1) ATE528304T1 (fr)
AU (2) AU2005267436A1 (fr)
BR (2) BRPI0512523A (fr)
CA (2) CA2570688A1 (fr)
CR (1) CR8831A (fr)
CY (1) CY1112124T1 (fr)
DK (1) DK1761522T3 (fr)
EA (2) EA200700119A1 (fr)
EC (2) ECSP067098A (fr)
ES (1) ES2372291T3 (fr)
HK (1) HK1104528A1 (fr)
HR (1) HRP20110761T1 (fr)
IL (2) IL180276A0 (fr)
MA (2) MA28729B1 (fr)
MX (2) MXPA06014716A (fr)
NO (2) NO20070470L (fr)
NZ (1) NZ550978A (fr)
PL (1) PL1761522T3 (fr)
PT (1) PT1761522E (fr)
RS (1) RS52064B (fr)
SI (1) SI1761522T1 (fr)
WO (2) WO2006012093A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003927A (es) * 2003-10-08 2008-02-07 Lilly Co Eli Compuestos y metodos para tratar dislipidemia.
DK1732933T3 (da) 2004-03-26 2008-10-27 Lilly Co Eli Forobindelser til behandling af dyslipidæmi
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
JP2008504266A (ja) 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
WO2007107843A1 (fr) * 2006-03-22 2007-09-27 Pfizer Products Inc. Procédés de traitement avec des inhibiteurs de la cetp
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
WO2008017381A1 (fr) 2006-08-08 2008-02-14 Sanofi-Aventis Imidazolidin-2,4-dione arylaminoaryl-alkyl-substituée, son procédé de fabrication, médicament contenant ce composé et son utilisation
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2157190B1 (fr) 2007-05-17 2017-05-03 EA Pharma Co., Ltd. Procédé de mesure de l'activité d'une enzyme modifiée par un lipide
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
EP2310372B1 (fr) 2008-07-09 2012-05-23 Sanofi Composés hétérocycliques, leur procédé de préparation, médicaments les contenant et leur utilisation
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
AR077208A1 (es) * 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
EP2470552B1 (fr) 2009-08-26 2013-11-13 Sanofi Nouveaux hydrates de fluoroglycoside hétéroaromatiques cristallins, produits pharmaceutiques comprenant ces composés et leur utilisation
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120057A1 (fr) 2011-03-08 2012-09-13 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683702B1 (fr) 2011-03-08 2014-12-24 Sanofi Nouveaux dérivés de phényle-oxathiazine substitués, leur procédé de fabrication, médicament contenant ces liaisons et son utilisation
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
AU2012282109B2 (en) * 2011-07-08 2016-06-23 Novartis Ag Method of treating atherosclerosis in high triglyceride subjects
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
DK2860175T3 (da) 2012-06-11 2018-01-29 Tacurion Fremgangsmåde til fremstilling af 4,4,7-trifluor-1,2,3,4-tetrahydro-5h-1-benzazepin-forbindelse og intermediat til syntese deraf
CN103958501B (zh) * 2012-07-16 2016-08-17 上海恒瑞医药有限公司 苯并七元杂环类衍生物、其制备方法及其在医药上的应用
WO2015119495A1 (fr) * 2014-02-05 2015-08-13 Dezima Pharma B.V. Inhibiteur de la protéine de transfert d'ester de cholestéryle (cetp) et compositions pharmaceutiques comprenant ledit inhibiteur pour leur utilisation dans le traitement ou la prévention de maladies cardiovasculaires
CN103833637B (zh) * 2014-03-31 2016-01-06 武汉武药制药有限公司 一种制备依塞曲匹（Evacetrapib）中间体的方法
TWI726888B (zh) 2015-06-09 2021-05-11 美商艾伯維有限公司 核受體調節劑
WO2016198908A1 (fr) 2015-06-09 2016-12-15 Abbvie Inc. Modulateurs des récepteurs nucléaires ror

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2402506A1 (fr) * 1977-09-09 1979-04-06 Guelennec Emile Le Cisaille pour la decoupe de ferrailles de grandes dimensions
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
CO5271716A1 (es) * 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
HU225777B1 (en) * 2001-04-30 2007-08-28 Pfizer Prod Inc Compounds useful as intermediates for 4-aminoquinoline derivatwes and process for producing them
BR0306208A (pt) 2002-08-30 2004-10-13 Japan Tobacco Inc Compostos de dibenzilamina e seu uso farmacêutico
JP2006508077A (ja) 2002-10-04 2006-03-09 ミレニアム・ファーマシューティカルズ・インコーポレイテッド 炎症疾患を治療するためのｐｇｄ２レセプタアンタゴニスト
EP1601655A2 (fr) 2003-03-04 2005-12-07 Takasago International Corporation Procede de production d'amines optiquement actives
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
MXPA06003927A (es) 2003-10-08 2008-02-07 Lilly Co Eli Compuestos y metodos para tratar dislipidemia.
DK1732933T3 (da) 2004-03-26 2008-10-27 Lilly Co Eli Forobindelser til behandling af dyslipidæmi
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
JP2008504266A (ja) 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
US7700774B2 (en) 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
AR077208A1 (es) * 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam

Also Published As

Publication number Publication date
JP2008504277A (ja) 2008-02-14
EA012585B1 (ru) 2009-10-30
IL180276A0 (en) 2007-07-04
JP2008504266A (ja) 2008-02-14
CA2570673C (fr) 2013-01-29
CA2570688A1 (fr) 2006-02-02
PL1761522T3 (pl) 2012-03-30
US20100204207A1 (en) 2010-08-12
AU2005267436A1 (en) 2006-02-02
ECSP067098A (es) 2007-01-26
MXPA06014716A (es) 2007-03-12
CY1112124T1 (el) 2015-11-04
US20080269284A1 (en) 2008-10-30
ATE528304T1 (de) 2011-10-15
ECSP067095A (es) 2007-01-26
SI1761522T1 (sl) 2012-02-29
EA200700119A1 (ru) 2007-10-26
DK1761522T3 (da) 2012-01-02
EA200700120A1 (ru) 2007-06-29
US20070244095A1 (en) 2007-10-18
CN1972932A (zh) 2007-05-30
MA28729B1 (fr) 2007-07-02
CA2570673A1 (fr) 2006-01-05
HRP20110761T1 (hr) 2011-11-30
RS52064B (en) 2012-06-30
WO2006002342A1 (fr) 2006-01-05
NO20070470L (no) 2007-03-26
CR8831A (es) 2008-11-13
NZ550978A (en) 2010-08-27
AU2005258241A1 (en) 2006-01-05
KR20070041452A (ko) 2007-04-18
JP4836945B2 (ja) 2011-12-14
EP1761522A1 (fr) 2007-03-14
US7786108B2 (en) 2010-08-31
WO2006012093A1 (fr) 2006-02-02
EP1761522B1 (fr) 2011-10-12
IL180277A (en) 2011-08-31
PT1761522E (pt) 2011-12-21
BRPI0512516A (pt) 2008-03-11
EP1761521A1 (fr) 2007-03-14
MA28730B1 (fr) 2007-07-02
EP2479175A1 (fr) 2012-07-25
BRPI0512523A (pt) 2008-03-11
HK1104528A1 (en) 2008-01-18
AU2005258241B2 (en) 2011-08-25
ES2372291T3 (es) 2012-01-18
IL180277A0 (en) 2007-07-04
MXPA06014706A (es) 2007-03-12
CN1972932B (zh) 2011-06-29

Similar Documents

Publication Publication Date Title
NO20070468L (no) Sammensetninger og fremgangsmater for behandling av dyslipidemi
NO20064763L (no) Forbindelser og fremgangsmater for behandling av dyslipidemi
WO2005111002A3 (fr) Derives de cycloalkyle substitues, leur procede de production et leur utilisation comme medicaments
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
DK1817301T3 (da) Forstærkere af glutamat-receptorer
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
DK2026803T3 (da) Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf
CY1112311T1 (el) Ενωσεις πυραζολινης ως ανταγωνιστες υποδοχεα αλατοκορτικοειδους
TW200745039A (en) Isotopically substituted pantoprazole
SE0303541D0 (sv) New compounds
ATE471312T1 (de) Diaryltriazolmethylamin-derivate sowie ihre herstellung und therapeutische verwendung
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины
SE0303090D0 (sv) Novel compounds
DK1951718T3 (da) 4-Oxadiazolyl-piperidinforbindelser og anvendelse deraf

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application